The medical management of opioid dependence in HIV primary care settings
- PMID: 17089480
- DOI: 10.1007/s11904-006-0016-z
The medical management of opioid dependence in HIV primary care settings
Abstract
Injecting drug use is a common mode of transmission among persons with HIV/AIDS. Many HIV-infected patients meet diagnostic criteria for opioid dependence, a chronic and relapsing brain disorder. Most HIV providers, however, receive little training in substance use disorders. Opioid agonist therapy (OAT) has a stabilizing effect on opioid-dependent patients and is associated with greater acceptance of antiretroviral (ARV) therapy, higher ARV adherence, and greater engagement in HIV-related health care. Although methadone maintenance has been the OAT gold standard, methadone is available for the treatment of opioid dependence only in strictly regulated narcotic treatment programs. Buprenorphine, a partial opioid agonist approved for the office-based treatment of opioid dependence in 2002, may result in better health and substance use treatment outcomes for patients with HIV disease.
Similar articles
-
Utilization of buprenorphine and methadone among opioid users who inject drugs.Subst Abus. 2018 Jan 2;39(1):83-88. doi: 10.1080/08897077.2017.1363844. Epub 2017 Sep 18. Subst Abus. 2018. PMID: 28796591 Free PMC article.
-
HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.Lancet HIV. 2021 Feb;8(2):e67-e76. doi: 10.1016/S2352-3018(20)30302-7. Lancet HIV. 2021. PMID: 33539760 Free PMC article. Clinical Trial.
-
Models for integrating buprenorphine therapy into the primary HIV care setting.Clin Infect Dis. 2006 Mar 1;42(5):716-21. doi: 10.1086/500200. Epub 2006 Jan 24. Clin Infect Dis. 2006. PMID: 16447120
-
Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward.Lancet. 2010 Jul 31;376(9738):355-66. doi: 10.1016/S0140-6736(10)60832-X. Lancet. 2010. PMID: 20650513 Review.
-
Opioid dependence: rationale for and efficacy of existing and new treatments.Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S173-7. doi: 10.1086/508180. Clin Infect Dis. 2006. PMID: 17109303 Review.
Cited by
-
Opioid-Mediated HIV-1 Immunopathogenesis.J Neuroimmune Pharmacol. 2020 Dec;15(4):628-642. doi: 10.1007/s11481-020-09960-5. Epub 2020 Oct 8. J Neuroimmune Pharmacol. 2020. PMID: 33029670 Free PMC article. Review.
-
Opiate Drugs with Abuse Liability Hijack the Endogenous Opioid System to Disrupt Neuronal and Glial Maturation in the Central Nervous System.Front Pediatr. 2018 Jan 23;5:294. doi: 10.3389/fped.2017.00294. eCollection 2017. Front Pediatr. 2018. PMID: 29410949 Free PMC article. Review.
-
Hepatitis infection in the treatment of opioid dependence and abuse.Subst Abuse. 2008 Apr 28;1:15-61. doi: 10.4137/sart.s580. eCollection 2008. Subst Abuse. 2008. PMID: 25977607 Free PMC article. Review.
-
Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca²⁺]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity.Curr HIV Res. 2014;12(6):424-34. doi: 10.2174/1570162x1206150311161147. Curr HIV Res. 2014. PMID: 25760046 Free PMC article.
-
The feasibility of an intensive case management program for injection drug users on antiretroviral therapy in St. Petersburg, Russia.Harm Reduct J. 2013 Sep 5;10:15. doi: 10.1186/1477-7517-10-15. Harm Reduct J. 2013. PMID: 24006958 Free PMC article.